French cinemas project optimism for 2026 after disappointing year

French cinema attendance fell to roughly 157 million tickets in 2025 versus 181 million in 2024, with the CNC attributing the decline to a shortage of French blockbusters and several underperforming U.S. releases (e.g., Mission: Impossible finale ~2.5m tickets). Art-house hits and year-end family tentpoles (Zootopia 2: 6.2m; Avatar 3: 4.6m) produced late momentum, and the CNC extended cash advances to 70 of ~2,200 cinemas while reporting no increase in closures year‑over‑year. Industry participants are cautiously optimistic about 2026 given a stronger December and a fuller French release slate (Marsupilami, Les Légendaires) alongside major global releases (Dune: Part 3 and Avengers: Doomsday) that could support exhibitors and studio revenues.

Analysis

Market structure: Winners are large IP owners and studios that can deliver 'event' tentpoles (Disney, major indie French producers) while art-house niches can still drive 6-figures-to-low-7-figure French box-office (Zootopia 2: 6.2m, Avatar 3: 4.6m). Losers are mid-tier US releases and undercapitalized cinemas without liquidity (CNC granted advances to 70/~2,200 venues) and pure-play streaming models that lack theatrical leverage. This reallocates pricing power to franchises and theatrical windows for event films, increasing variance in studio cashflows.

Risk assessment: Tail risks include a simultaneous Dune Part 3 vs Avengers release ("Dunesday") that could split global box office and depress per-title revenues, and EU regulatory changes on theatrical windowing that could force faster streamer access (negative for exhibitors). Immediate risk (days–weeks): weekly box-office volatility (attendance swung +30% week of Dec 17–24). Medium (months): release calendar concentration into Feb and Dec 2026; long (quarters/years): durable audience shift among seniors and younger event-based consumption.

Trade implications: Tactical long DIS exposure (IP + parks + theatrical upside) and modest defensive short or put exposure to pure-streamers (NFLX) to capture rotation into theatrical tentpoles. Use options to cap downside: buy DIS Jan 2027 110/150 call spread (limited cost, levered upside into 2026/27 tentpoles) and buy NFLX 3–6 month puts as a hedge against subscriber reallocation. Rotate into exhibitors/European leisure names only after confirming sustained weekly attendance >+10% vs 2024 for 4 consecutive weeks.

Contrarian angles: Consensus underestimates mid-tier French nostalgia/IP (Les Légendaires, Marsupilami) as reliable holiday cash generators; market may be underpricing Disney’s sequels but overpricing the hit-probability of mid-budget US films. Historical analog: post-2000s cyclical rebound driven by tentpoles can deliver 15–30% revenue lift for studios in a single season. Monitor box-office thresholds (France: >5–7m tickets per title = breakout) and EU windowing rule signals as triggers to reweight positions.

Key Decisions for Investors

• Establish a 2–3% long position in DIS (Disney) sized to portfolio, and overlay a Jan 2027 110/150 call spread (buy Jan 2027 110C, sell Jan 2027 150C) to capture upside from 2026 tentpoles while capping premium outlay; scale in ahead of Feb 2026 holiday slate and add to size if French/US weekly attendance stays >+10% vs 2024 for 4 weeks.
• Initiate a 0.5–1% notional hedge: buy NFLX 3–6 month puts (strike ~5–8% OTM) or establish a small short (equal-$) vs DIS to play relative underperformance of pure-streamers if theatrical revivals accelerate; exit if NFLX put IV < 20% or DIS outperforms by >15% in 60 days.
• Construct a pair trade: go long select French/European leisure/exhibition equities or ETF (target ~1–2% exposure) vs short mid-budget US studio ETFs/indices if weekly French admissions fail to recover (trigger to increase short size: national annual tickets <160m).
• Do not increase exposure to exhibitors/parks beyond tactical sizing until two catalysts are met: (1) consistent quarter-over-quarter attendance improvement (>=+10% vs 2024) and (2) clarity on EU windowing rules (no major relaxation) within 6 months; otherwise keep allocations <3% of equities sleeve.